# A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

> **NCT04505098** · PHASE4 · TERMINATED · sponsor: **Kaiser Permanente** · enrollment: 39600 (actual)

## Conditions studied

- Covid19
- Atherosclerosis
- Cardiovascular Diseases
- Upper Respiratory Tract Infections

## Interventions

- **DRUG:** Icosapent ethyl

## Key facts

- **NCT ID:** NCT04505098
- **Lead sponsor:** Kaiser Permanente
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-07
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 39600 (ACTUAL)
- **Why stopped:** The study was suspended by the IRB of record and subsequently terminated
- **Last updated:** 2023-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04505098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04505098, "A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04505098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*